Salem, NH, June 26, 2012 --(PR.com
)-- ALPCO Diagnostics
, a leading developer, manufacturer and distributor of assays, is pleased to announce the launch of their new site specific rat kidney injury biomarker, Alpha Glutathione-S-Transferase (aGST)
a constitutive proximal tubule injury marker. The biomarker has been widely referenced in scientific publications as well as studied by the ILSI HESI Committee on the Application of Biomarkers of Toxicity, Nephrotoxicity Working Group. Results of this collaborative study have been submitted to various U.S., EU and Japanese regulatory as part of the FDA CDER biomarker qualification initiative.
Karen Stein, Vice President of Sales and Marketing at ALPCO said, “We are focused on expanding our product offering in the Kidney Injury
arena as well as building our product development/ manufacturing so we are delighted to enter into this collaboration with Argutus Medical. Argutus is well-known in the kidney injury field and their reagents are considered the gold standard by many. We are confident this relationship will see continued success with these assays as tools in the early detection of nephrotoxicity in research & preclinical drug development.”
Joe Keenan, General Manager at Argutus
said, “We are very excited about the potential of our collaboration with ALPCO. Having our ever popular rat-alpha GST marker available on a 96 well plate once again will serve those customers with a need to run single analyte assays for their key projects. Many of our prior customers for these kits have been eagerly awaiting the re-launch of this individual assay and with our strong partnership with ALPCO we look forward to making further assays available in the near future.”
The rat α-GST assay can be purchased directly from ALPCO or through any of its international distributors. Also, RPA-1 should be available late summer.